Cyproterone (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cyproterone" in English language version.

refsWebsite
Global rank English rank
2nd place
2nd place
4th place
4th place
3rd place
3rd place
11th place
8th place
5th place
5th place
6th place
6th place
low place
low place
1,182nd place
725th place

archive.org

  • Schröder FH, Radlmaier A (2009). "Steroidal Antiandrogens". In Jordan VC, Furr BJ (eds.). Hormone Therapy in Breast and Prostate Cancer. Cancer Drug Discovery and Development. Humana Press. pp. 325–346. doi:10.1007/978-1-59259-152-7_15. ISBN 978-1-60761-471-5. The progestational effect [of CPA] is linked to the presence of the acetyl group at position C17 of the steroid. Consequently, the free alcohol of CPA, cyproterone, which lacks the acetyl group, is devoid of progestational properties. However, it still exerts antiandrogenic activity, although less pronounced than CPA. Consequently, cyproterone was the first compound falling into the nowadays well-known class of pure antiandrogens.

books.google.com

  • Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 339–. ISBN 978-1-4757-2085-3.
  • Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 289. ISBN 978-3-88763-075-1. Retrieved 29 May 2012.
  • Orfanos CE, Happle R (1990). Hair and Hair Diseases. Springer Science & Business Media. pp. 1197–. ISBN 978-3-642-74612-3.
  • Sawyer CH, Gorski RA (1971). Steroid Hormones and Brain Function. University of California Press. pp. 366–. ISBN 978-0-520-01887-7.
  • Hughes A, Hasan SH, Oertel GW, Voss HE, Bahner F, Neumann F, et al. (27 November 2013). Androgens II and Antiandrogens / Androgene II und Antiandrogene. Springer Science & Business Media. pp. 279–. ISBN 978-3-642-80859-3. The only chemical difference between cyproterone and cyproterone acetate consists of a free or esterified hydroxyl group at C17 but this difference accounts for profound differences in the mechanism of action and possibilities for use in the intact organism. Both steroids are highly active antiandrogens at any route of administration, the acetate has a greater antiandrogenic potency than the free alcohol. With the exception of a slight depressive effect on the adrenals, cyproterone does not have other side-activities unrelated to antiandrogenicity. It has, therefore, been termed "pure antiandrogen". Cyproterone acetate has one major additional activity: it is one of the strongest gestagens that have ever been synthesized [23, 70, 32, 77], [...]
  • Labhart A (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 473–. ISBN 978-3-642-96158-8. Cyproterone acetate is 250 and 3330 times as potent a progestational agent as progesterone and cyproterone alcohol (10< respectively (Clauberg assay). [...] The pure anti-androgens, such as cyproteron, block the receptors of the negative feedback system. An uninhibited secretion of the releasing factors and an increased production of gonadotropins results, so that the inhibitory effect on the endorgans may finally be overcome by overpoduction of testosterone (Neumann, 1971). Cyproterone acetate, however, with its marked progestational effect, inhibits the release of LH and FSH at the same time and thus has a lasting anti-androgenic effect (Neumann, 1970). Thus, cyproteron leads to an increase in LH, whereas cyproteron acetate inhibits both LH and FSH.
  • Craig JV, Furr BJ (5 February 2010). Hormone Therapy in Breast and Prostate Cancer. Springer Science & Business Media. pp. 326–. ISBN 978-1-59259-152-7.
  • Raspé G (1969). Schering Workshop on Steroid Metabolism: "in vitro versus in vivo.". Pergamon Press. ISBN 9780080175447. [...] In this investigation a number of normal male volunteers were treated for three weeks with 100 mg free cyproterone per day. Sebum production was measured by the Straufi-Pochi method before treatment and on the 7th, 10th, 11th, 15th, 18th, [...]
  • Jacobs HS (1979). Advances in gynaecological endocrinology: proceedings of the Sixth Study Group of the Royal College of Obstetricians and Gynaecologists, 18th and 19th October, 1978. Great Britain \): Royal College of Obstetricians and Gynaecologists. p. 367. ISBN 978-0-87489-225-3. Limited clinical experience also exists with benorterone, the first anti-androgen tried in man, and with free cyproterone. In the late sixties benorterone was reported to give promising results in 93 androgenized women but was soon withdrawn from clinical trial, mainly because of the development of gynaecomastia in the male. As a big advantage compared with CPA, it was found to be effective not only orally but also topically. Free cyproterone, on the other hand, proved to be without clinical value for reasons that cannot be discussed here. Thus we are left with CPA as the only anti-androgen that is already on the market in several countries.

doi.org

edpsciences.org

rnd.edpsciences.org

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Giorgi EP, Shirley IM, Grant JK, Stewart JC (March 1973). "Androgen dynamics in vitro in the human prostate gland. Effect of cyproterone and cyproterone acetate". The Biochemical Journal. 132 (3): 465–474. doi:10.1042/bj1320465. PMC 1177610. PMID 4125095. Cyproterone (6-chloro-17-hydroxy-1,2α-methylenepregna-4,6-diene-3,20-dione) and cyproterone acetate (17-acetoxy-6-chloro-1,2α-methylene-pregna-4,6-diene-3,20-dione) are powerful anti-androgens, which exert multiple actions in many species. Cyproterone acetate has three times the anti-androgenic potency of cyproterone, and also has some progestational properties (for review, see Neumann et al., 1970). [...] Cyproterone seemed to decrease the activity of 17α-hydroxysteroid dehydrogenase and of 5α-steroid reductase in human prostate in vitro, as it does in testes and liver of rats (Breuer & Hoffmann, 1967; Hoffmann & Breuer, 1968; Denef et al., 1968). Cyproterone acetate did not seem to have any direct effect on the activity of these two enzymes.
  • Spona J, Schneider WH, Bieglmayer C, Schroeder R, Pirker R (1979). "Ovulation inhibition with different doses of levonorgestrel and other progestogens: clinical and experimental investigations". Acta Obstetricia et Gynecologica Scandinavica Supplement. 88 (s88): 7–15. doi:10.3109/00016347909157223. PMID 393050. S2CID 30486799. Cyproterone which has a very weak biological progestogen potency exhibited low affinity for the progestogen-receptor (Table I).
  • Steinbeck H, Mehring M, Neumann F (July 1971). "Comparison of the effects of cyproterone, cyproterone acetate and oestradiol on testicular function, accessory sexual glands and fertility in a long-term study on rats". Journal of Reproduction and Fertility. 26 (1): 65–76. doi:10.1530/jrf.0.0260065. PMID 5091295.
  • Ewing LL, Robaire B (1978). "Endogenous antispermatogenic agents: prospects for male contraception". Annual Review of Pharmacology and Toxicology. 18 (1): 167–187. doi:10.1146/annurev.pa.18.040178.001123. PMID 206192. Cyproterone (6-chloro-17a-hydroxy-1a,2a-methylene-pregna-4,6-diene-3,20-dione) and cyproterone acetate have received considerable attention as antispermatogenic substances. Cyproterone, which has·only weak antigonadotropic properties, was found to be a poor antispermatogenic agent (42). In contrast, cyproterone acetate, which inhibits gonadotropin secretion, was found to be an antispermatogenic agent (142).
  • Stewart ME, Pochi PE (April 1978). "Antiandrogens and the skin". International Journal of Dermatology. 17 (3): 167–179. doi:10.1111/j.1365-4362.1978.tb06057.x. PMID 148431. S2CID 43649686. While CPA alone probably suppresses ovulation, cyproterone, which possesses no progestational activity, does not!8,72
  • Broulik PD, Starka L (November 1975). "Corticosteroid-like effect of cyproterone and cyproterone acetate in mice". Experientia. 31 (11): 1364–1365. doi:10.1007/bf01945829. PMID 1204803. S2CID 11452300.
  • Gutiérrez M, Menéndez L, Brieva R, Hidalgo A, Baamonde A (November 1998). "Different types of steroids inhibit [3H]diprenorphine binding in mouse brain membranes". General Pharmacology. 31 (5): 747–751. doi:10.1016/s0306-3623(98)00110-4. PMID 9809473.
  • Walsh PC, Swerdloff RS, Odell WD (June 1972). "Cyproterone: effect on serum gonadotropins in the male". Endocrinology. 90 (6): 1655–1659. doi:10.1210/endo-90-6-1655. PMID 5020316.
  • Rager K, Huenges R, Gupta D, Bierich JR (October 1973). "The treatment of precocious puberty with cyproterone acetate". Acta Endocrinologica. 74 (2): 399–408. doi:10.1530/acta.0.0740399. PMID 4270254. Free cyproterone was first tried as a therapy for precocious puberty by Bierich (1970, 1971). The results, however, did not show any significant improvement.

ncbi.nlm.nih.gov

  • Giorgi EP, Shirley IM, Grant JK, Stewart JC (March 1973). "Androgen dynamics in vitro in the human prostate gland. Effect of cyproterone and cyproterone acetate". The Biochemical Journal. 132 (3): 465–474. doi:10.1042/bj1320465. PMC 1177610. PMID 4125095. Cyproterone (6-chloro-17-hydroxy-1,2α-methylenepregna-4,6-diene-3,20-dione) and cyproterone acetate (17-acetoxy-6-chloro-1,2α-methylene-pregna-4,6-diene-3,20-dione) are powerful anti-androgens, which exert multiple actions in many species. Cyproterone acetate has three times the anti-androgenic potency of cyproterone, and also has some progestational properties (for review, see Neumann et al., 1970). [...] Cyproterone seemed to decrease the activity of 17α-hydroxysteroid dehydrogenase and of 5α-steroid reductase in human prostate in vitro, as it does in testes and liver of rats (Breuer & Hoffmann, 1967; Hoffmann & Breuer, 1968; Denef et al., 1968). Cyproterone acetate did not seem to have any direct effect on the activity of these two enzymes.

patents.google.com

semanticscholar.org

api.semanticscholar.org

  • Spona J, Schneider WH, Bieglmayer C, Schroeder R, Pirker R (1979). "Ovulation inhibition with different doses of levonorgestrel and other progestogens: clinical and experimental investigations". Acta Obstetricia et Gynecologica Scandinavica Supplement. 88 (s88): 7–15. doi:10.3109/00016347909157223. PMID 393050. S2CID 30486799. Cyproterone which has a very weak biological progestogen potency exhibited low affinity for the progestogen-receptor (Table I).
  • Stewart ME, Pochi PE (April 1978). "Antiandrogens and the skin". International Journal of Dermatology. 17 (3): 167–179. doi:10.1111/j.1365-4362.1978.tb06057.x. PMID 148431. S2CID 43649686. While CPA alone probably suppresses ovulation, cyproterone, which possesses no progestational activity, does not!8,72
  • Broulik PD, Starka L (November 1975). "Corticosteroid-like effect of cyproterone and cyproterone acetate in mice". Experientia. 31 (11): 1364–1365. doi:10.1007/bf01945829. PMID 1204803. S2CID 11452300.

worldcat.org

search.worldcat.org